Organon (OGN) Stock Forecast, Price Target & Predictions
OGN Stock Forecast
Organon stock forecast is as follows: an average price target of $24.00 (represents a 64.61% upside from OGN’s last price of $14.58) and a rating consensus of 'Hold', based on 3 wall street analysts offering a 1-year stock forecast.
OGN Price Target
The average price target for Organon (OGN) is $24.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $24.00 to $24.00. This represents a potential 64.61% upside from OGN's last price of $14.58.
OGN Analyst Ratings
According to 3 Wall Street analysts, Organon's rating consensus is 'Hold'. The analyst rating breakdown for OGN stock is 0 'Strong Buy' (0.00%), 1 'Buy' (33.33%), 2 'Hold' (66.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Organon Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 29, 2024 | David Amsellem | Piper Sandler | $24.00 | $18.84 | 27.35% | 64.61% |
| Jun 26, 2023 | David Amsellem | Piper Sandler | $34.00 | $20.36 | 66.95% | 133.20% |
The latest Organon stock forecast, released on Apr 29, 2024 by David Amsellem from Piper Sandler, set a price target of $24.00, which represents a 27.35% increase from the stock price at the time of the forecast ($18.84), and a 64.61% increase from OGN last price ($14.58).
Organon Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $24.00 |
| Last Closing Price | $14.58 | $14.58 | $14.58 |
| Upside/Downside | -100.00% | -100.00% | 64.61% |
In the current month, the average price target of Organon stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Organon's last price of $14.58. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 17, 2024 | Goldman Sachs | Neutral | Neutral | Hold |
| Apr 29, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Mar 13, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jan 12, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Dec 12, 2023 | Piper Sandler | Overweight | Overweight | Hold |
| Nov 09, 2023 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 08, 2023 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| May 09, 2023 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Sep 06, 2022 | Piper Sandler | Overweight | Upgrade | |
| Apr 27, 2022 | Goldman Sachs | Buy | Initialise | |
| Feb 22, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
Organon's last stock rating was published by Goldman Sachs on Dec 17, 2024. The company gave OGN a "Neutral" rating, the same as its previous rate.
Organon Financial Forecast
Organon Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $1.60B | $1.52M | $1.61M | $1.54B | $1.49B | $1.54B | $1.58B | $1.57B | $1.60B | $1.60B | $1.59B | $1.51B |
| Avg Forecast | $1.58B | $1.57B | $1.61B | $1.60B | $1.59B | $1.56B | $1.61B | $1.57B | $1.55B | $1.57B | $1.57B | $1.54B | $1.49B | $1.51B | $1.53B | $1.52B | $1.57B | $1.58B | $1.52B | $1.57B |
| High Forecast | $1.60B | $1.59B | $1.63B | $1.62B | $1.60B | $1.56B | $1.61B | $1.57B | $1.59B | $1.60B | $1.58B | $1.56B | $1.51B | $1.51B | $1.53B | $1.52B | $1.57B | $1.58B | $1.52B | $1.57B |
| Low Forecast | $1.57B | $1.55B | $1.59B | $1.58B | $1.58B | $1.56B | $1.61B | $1.56B | $1.52B | $1.56B | $1.55B | $1.52B | $1.47B | $1.51B | $1.53B | $1.52B | $1.57B | $1.58B | $1.52B | $1.57B |
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 3 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | 1.03% | 0.00% | 0.00% | 1.00% | 0.99% | 1.02% | 1.03% | 1.03% | 1.02% | 1.01% | 1.05% | 0.96% |
Organon's average Quarter revenue forecast for Mar 24 based on 1 analysts is $1.57B, with a low forecast of $1.56B, and a high forecast of $1.57B. OGN's average Quarter revenue forecast represents a -2.05% decrease compared to the company's last Quarter revenue of $1.60B (Dec 23).
Organon EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 3 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | $370.00M | $232.00K | $389.00K | $388.00M | $279.00M | $415.00M | $482.00M | $539.00M | $396.00M | $539.00M | $538.00M | $509.00M |
| Avg Forecast | $537.90M | $533.54M | $546.33M | $544.60M | $539.96M | $530.94M | $547.35M | $692.28M | $527.59M | $534.42M | $531.38M | $547.26M | $393.78M | $520.33M | $526.71M | $432.62M | $540.61M | $543.51M | $454.95M | $539.18M |
| High Forecast | $543.67M | $539.26M | $552.19M | $550.44M | $543.40M | $531.28M | $547.35M | $830.74M | $541.20M | $543.54M | $537.08M | $656.71M | $472.54M | $520.33M | $526.71M | $519.14M | $540.61M | $543.51M | $545.94M | $539.18M |
| Low Forecast | $531.30M | $526.99M | $539.63M | $537.92M | $536.52M | $530.60M | $547.35M | $553.83M | $517.38M | $529.00M | $524.86M | $437.81M | $315.03M | $520.33M | $526.71M | $346.09M | $540.61M | $543.51M | $363.96M | $539.18M |
| Surprise % | - | - | - | - | - | - | - | - | 0.70% | 0.00% | 0.00% | 0.71% | 0.71% | 0.80% | 0.92% | 1.25% | 0.73% | 0.99% | 1.18% | 0.94% |
1 analysts predict OGN's average Quarter EBITDA for Mar 24 to be $692.28M, with a high of $830.74M and a low of $553.83M. This is 87.10% upper than Organon's previous annual EBITDA (Dec 23) of $370.00M.
Organon Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 3 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| Net Income | - | - | - | - | - | - | - | - | $546.00M | $58.00K | $242.00K | $177.00M | $108.00M | $227.00M | $234.00M | $348.00M | $202.00M | $323.00M | $427.00M | $399.00M |
| Avg Forecast | $261.49M | $250.23M | $266.90M | $267.55M | $240.22M | $234.67M | $279.39M | $406.95M | $210.66M | $272.81M | $252.66M | $321.70M | $200.87M | $284.83M | $303.30M | $254.31M | $321.42M | $372.32M | $361.09M | $447.37M |
| High Forecast | $265.14M | $253.72M | $270.62M | $271.28M | $256.79M | $246.70M | $279.44M | $488.34M | $281.76M | $280.46M | $256.18M | $386.04M | $241.04M | $284.83M | $305.66M | $305.17M | $321.42M | $372.32M | $433.30M | $447.37M |
| Low Forecast | $257.32M | $246.24M | $262.64M | $263.28M | $223.65M | $222.65M | $279.33M | $325.56M | $179.06M | $265.16M | $248.62M | $257.36M | $160.70M | $284.83M | $300.94M | $203.45M | $321.42M | $372.32M | $288.87M | $447.37M |
| Surprise % | - | - | - | - | - | - | - | - | 2.59% | 0.00% | 0.00% | 0.55% | 0.54% | 0.80% | 0.77% | 1.37% | 0.63% | 0.87% | 1.18% | 0.89% |
Organon's average Quarter net income forecast for Mar 24 is $406.95M, with a range of $325.56M to $488.34M. OGN's average Quarter net income forecast represents a -25.47% decrease compared to the company's last Quarter net income of $546.00M (Dec 23).
Organon SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 3 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| SG&A | - | - | - | - | - | - | - | - | $469.00M | $538.00K | $451.00K | $435.00M | $470.00M | $440.00M | $423.00M | $371.00M | $482.00M | $388.00M | $416.00M | $382.00M |
| Avg Forecast | $391.10M | $387.92M | $397.22M | $395.97M | $392.59M | $386.03M | $397.97M | $433.85M | $383.60M | $388.57M | $386.35M | $342.96M | $479.30M | $373.75M | $378.33M | $271.12M | $388.31M | $390.39M | $351.79M | $387.28M |
| High Forecast | $395.29M | $392.09M | $401.49M | $400.21M | $395.09M | $386.28M | $397.97M | $520.61M | $393.50M | $395.19M | $390.50M | $411.55M | $575.16M | $373.75M | $378.33M | $325.34M | $388.31M | $390.39M | $422.14M | $387.28M |
| Low Forecast | $386.30M | $383.16M | $392.35M | $391.11M | $390.09M | $385.78M | $397.97M | $347.08M | $376.17M | $384.62M | $381.61M | $274.37M | $383.44M | $373.75M | $378.33M | $216.89M | $388.31M | $390.39M | $281.43M | $387.28M |
| Surprise % | - | - | - | - | - | - | - | - | 1.22% | 0.00% | 0.00% | 1.27% | 0.98% | 1.18% | 1.12% | 1.37% | 1.24% | 0.99% | 1.18% | 0.99% |
Organon's average Quarter SG&A projection for Mar 24 is $433.85M, based on 1 Wall Street analysts, with a range of $347.08M to $520.61M. The forecast indicates a -7.50% fall compared to OGN last annual SG&A of $469.00M (Dec 23).
Organon EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 3 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| EPS | - | - | - | - | - | - | - | - | $2.13 | - | - | $0.70 | $0.42 | $0.89 | $0.92 | $1.37 | $0.80 | $1.27 | $1.68 | $1.58 |
| Avg Forecast | $1.01 | $0.96 | $1.03 | $1.03 | $0.92 | $0.90 | $1.08 | $0.98 | $0.81 | $1.05 | $0.97 | $1.17 | $0.92 | $1.10 | $1.17 | $1.30 | $1.24 | $1.44 | $1.42 | $1.73 |
| High Forecast | $1.02 | $0.98 | $1.04 | $1.04 | $0.99 | $0.95 | $1.08 | $0.98 | $1.08 | $1.08 | $0.99 | $1.18 | $0.93 | $1.10 | $1.18 | $1.36 | $1.24 | $1.44 | $1.42 | $1.73 |
| Low Forecast | $0.99 | $0.95 | $1.01 | $1.01 | $0.86 | $0.86 | $1.08 | $0.98 | $0.69 | $1.02 | $0.96 | $1.15 | $0.91 | $1.10 | $1.16 | $1.24 | $1.24 | $1.44 | $1.42 | $1.73 |
| Surprise % | - | - | - | - | - | - | - | - | 2.63% | 0.00% | 0.00% | 0.60% | 0.46% | 0.81% | 0.78% | 1.05% | 0.64% | 0.88% | 1.19% | 0.91% |
According to 1 Wall Street analysts, Organon's projected average Quarter EPS for Mar 24 is $0.98, with a low estimate of $0.98 and a high estimate of $0.98. This represents a -54.09% decrease compared to OGN previous annual EPS of $2.13 (Dec 23).
Organon Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BIIB | Biogen | $150.64 | $251.82 | 67.17% | Buy |
| OGN | Organon | $14.77 | $24.00 | 62.49% | Hold |
| MRK | Merck | $100.06 | $135.83 | 35.75% | Buy |
| LLY | Eli Lilly and Company | $778.62 | $1.03K | 31.80% | Buy |
| AZN | AstraZeneca | $67.18 | $88.00 | 30.99% | Buy |
| AMGN | Amgen | $265.95 | $338.22 | 27.17% | Buy |
| SNY | Sanofi | $48.94 | $62.00 | 26.69% | Buy |
| PFE | Pfizer | $26.43 | $32.83 | 24.21% | Hold |
| NVS | Novartis | $99.10 | $120.50 | 21.59% | Hold |
| ABBV | AbbVie | $175.38 | $211.20 | 20.42% | Buy |
| JNJ | Johnson & Johnson | $146.41 | $175.13 | 19.62% | Buy |
| GILD | Gilead Sciences | $92.80 | $87.30 | -5.93% | Buy |
| BMY | Bristol-Myers Squibb Company | $57.65 | $50.50 | -12.40% | Hold |